Cheap version of Merck COVID pill to be made for poorer nations
The antiviral drug, which received emergency approval in the United States in December, reduces hospitalizations and deaths of high-risk patients by around 30%, according to clinical trial results.
An experimental COVID-19 treatment pill, called molnupiravir and being developed by Merck & Co Inc and Ridgeback Biotherapeutics LP, is seen in this undated handout photo released by Merck & Co Inc and obtained by Reuters on October 26, 2021.(photo credit: MERCK & CO INC/HANDOUT VIA REUTERS)ByREUTERSUpdated:
